The seventh edition of the International Multidisciplinary Course on Iron Deficiency (IMCID) is going to take place in Rome, at the NH Collection Roma Vittorio Veneto, on Friday 8th and Saturday 9th March 2019.
The Course is organised by PharmaNutra S.p.A., in partnership with Zambon, and it will host expert doctors and researchers from all over the world, confirming the real international dimension of the event. The main objective of the International Multidisciplinary Course on Iron Deficiency is to present to medical specialists focuses and updates about iron deficiency.
As it has been highlighted during the 6th edition of the IMCID, held in Lisbon last year, anaemia is one of the most widespread diseases in the world and more than 50% of cases are due to iron deficiency. Because of iron’s intrinsic characteristics, the treatment of iron deficiency can be problematic for many patients, who are unlikely to tolerate iron intake and are forced to resort to intravenous intake or even to interrupt the treatment.
In this context, Sucrosomial Iron®, a unique patent held by PharmaNutra, represents a real innovation, because despite being an oral formulation, it demonstrates higher tolerability and bioavailability compared to traditional irons. During the seventh edition of the IMCID, speakers will present data and results of the latest clinical trials developed with the use of Sucrosomial Iron®.
The seventh edition of the International Multidisciplinary Course on Iron Deficiency is going to be preside over by Doctor Sandro Barni, Director of the Oncology Department and the Medical Oncology Unit of the Ospedale di Treviglio (Italy). The Scientific Commettee is formed by Doctor Barni himself, in collaboration with Doctor Manuel Muñoz, of the Department of Surgical Specialties, Biochemistry and Immunology of the University of Malaga (Spain) and Member of the NATA’s Board of Directors, and with Doctor Germano Tarantino, Chief Scientific Officer of PharmaNutra SpA.
The program of the first day is going to be focused on the problem of iron deficiency and iron supplementation in Pediatrics and Gynecology. In addition, there is going to be a general introduction on the mechanism of action of Sucrosomial Iron® and pre-clinical evidences on its use. The program of the second day is going to examine in depth the use of Sucrosomial Iron® in the treatment of iron deficiency in different clinical contexts. In particular, speakers are going to analise experiences with Sucrosomial Iron® in inflammatory bowel disease, in nephrology, oncology and internal medicine. A final focus on PBM (patient blood management) is going to conclude the seventh edition of the International Multidisciplinary Course on Iron Deficiency.